ES2180579T3 - Transferencia de genes en celulas epiteliales pancreaticas. - Google Patents

Transferencia de genes en celulas epiteliales pancreaticas.

Info

Publication number
ES2180579T3
ES2180579T3 ES94916720T ES94916720T ES2180579T3 ES 2180579 T3 ES2180579 T3 ES 2180579T3 ES 94916720 T ES94916720 T ES 94916720T ES 94916720 T ES94916720 T ES 94916720T ES 2180579 T3 ES2180579 T3 ES 2180579T3
Authority
ES
Spain
Prior art keywords
transfer
epithelial cells
genes
pancreatic epithelial
genetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94916720T
Other languages
English (en)
Inventor
James M Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
University of Michigan Ann Arbor
Original Assignee
University of Michigan System
University of Michigan Ann Arbor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System, University of Michigan Ann Arbor filed Critical University of Michigan System
Application granted granted Critical
Publication of ES2180579T3 publication Critical patent/ES2180579T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4712—Cystic fibrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A LOS METODOS PARA LA TRANSFERENCIA GENETICA SOMATICA Y SELECTIVA A LAS CELULAS EPITELIALES PANCREATICAS O BILIARES DE UN PACIENTE. EL METODO DE ESTA INVENCION COMPRENDE LA INTRODUCCION DEL GEN QUE HA DE TRANSFERIRSE, ASOCIADO CON UN VEHICULO DE TRANSFERENCIA APROPIADO, EN EL SISTEMA DUCTAL TANTO DEL PANCREAS COMO DEL HIGADO. DE FORMA MAS ESPECIFICA, LA INVENCION SE REFIERE A LA APLICACION DE ESTAS TECNICAS PARA TRATAR LAS ENFERMEDADES GENETICAS, COMO LA FIBROSIS QUISTICA, QUE SE CARACTERIZAN POR DEFECTOS GENETICOS DE ESTAS CELULAS EPITELIALES.
ES94916720T 1993-05-10 1994-05-10 Transferencia de genes en celulas epiteliales pancreaticas. Expired - Lifetime ES2180579T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5989993A 1993-05-10 1993-05-10

Publications (1)

Publication Number Publication Date
ES2180579T3 true ES2180579T3 (es) 2003-02-16

Family

ID=22026003

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94916720T Expired - Lifetime ES2180579T3 (es) 1993-05-10 1994-05-10 Transferencia de genes en celulas epiteliales pancreaticas.

Country Status (11)

Country Link
US (1) US20050048043A1 (es)
EP (2) EP0698109B1 (es)
JP (1) JPH08509869A (es)
AT (1) ATE221575T1 (es)
AU (1) AU6829994A (es)
CA (1) CA2162602A1 (es)
DE (1) DE69431106T2 (es)
DK (1) DK0698109T3 (es)
ES (1) ES2180579T3 (es)
PT (1) PT698109E (es)
WO (1) WO1994026915A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US6107027A (en) * 1994-12-14 2000-08-22 University Of Washington Ribozymes for treating hepatitis C
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US6531455B1 (en) 1995-03-24 2003-03-11 The Regents Of The University Of California Delivery of polynucleotides by secretory gland expression
US5885971A (en) 1995-03-24 1999-03-23 The Regents Of The University Of California Gene therapy by secretory gland expression
US5837693A (en) * 1995-03-24 1998-11-17 The Regents Of The University Of California Intravenous hormone polypeptide delivery by salivary gland expression
US5830878A (en) 1995-06-07 1998-11-03 Megabios Corporation Cationic lipid: DNA complexes for gene targeting
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6254862B1 (en) 1997-03-03 2001-07-03 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US7011976B1 (en) 1997-03-03 2006-03-14 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
WO1997005898A1 (en) * 1995-08-03 1997-02-20 The Johns Hopkins University School Of Medicine Delivery of an agent to the ductal epithelium in the prophylactic and therapeutic treatment of cancer
US5763415A (en) * 1995-08-03 1998-06-09 John Hopkins University School Of Medicine Destruction of the epithelium of an exocrine gland in the prophylactic and therapeutic treatment of cancer
EP0845045A4 (en) * 1995-08-14 1999-11-24 Cornell Res Foundation Inc REGULATION OF CELL FUNCTIONS USING ECTOPIC EXPRESSION OF NON-ENDOGENOUS CELL SIGNALING RECEPTORS
CA2179341A1 (en) * 1996-04-12 1997-10-13 Gregory S. Korbutt Methods for isolating, enriching and increasing the maturation of cells
AU5926998A (en) * 1997-01-21 1998-08-07 Wisconsin Alumni Research Foundation Treatment of diabetes with synthetic beta cells
US6352857B1 (en) 1997-01-21 2002-03-05 Wisconsin Alumni Research Foundation Treatment of diabetes with synthetic beta cells
US6056687A (en) 1997-12-04 2000-05-02 American Medical Systems, Inc. Device for alleviating urinary incontinence
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6030337A (en) * 1998-07-30 2000-02-29 American Medical Systems, Inc. Continence augmentor and methods for urinary control
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
WO2003104467A1 (en) 2002-04-25 2003-12-18 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
WO2001096587A2 (en) * 2000-06-13 2001-12-20 The Children's Hospital Of Philadelphia Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus
DE60138403D1 (de) 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
JP2004532822A (ja) * 2001-03-14 2004-10-28 アビジェン， インコーポレイテッド ビリオンの管逆行感染による組換えアデノ随伴ウイルス媒介遺伝子移入
JP2003189875A (ja) * 2001-12-28 2003-07-08 Japan Science & Technology Corp 膵β細胞関連転写因子の遺伝子導入によるインスリン産生細胞の形成誘導
RU2468765C1 (ru) * 2011-09-02 2012-12-10 Радик Рашитович Хафизов Устройство для однопортовой лапароскопической санации, дренирования сальниковой сумки, брюшной полости при деструктивных формах острого панкреатита

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4755167A (en) * 1984-04-10 1988-07-05 Research Corporation In vivo method for distribution and stirring of therapeutic agents
IL79289A (en) * 1985-07-05 1992-01-15 Whitehead Biomedical Inst Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus
DE3752347T2 (de) * 1986-05-20 2002-09-26 The General Hospital Corp., Boston Verfahren zur pharmakokinetischen Studie der Insulin-Expression mit nicht-menschlichem Transgen-Säugetier
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5240846A (en) * 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
DE69233725T2 (de) * 1991-06-28 2009-02-12 The Regents Of The University Of Michigan, Ann Arbor Verwendung von DNA oder RNA zur Herstellung eines Medikaments zur Behandlung von Tumoren
DE69233013T2 (de) * 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
US5885971A (en) * 1995-03-24 1999-03-23 The Regents Of The University Of California Gene therapy by secretory gland expression

Also Published As

Publication number Publication date
DE69431106T2 (de) 2003-05-08
WO1994026915A1 (en) 1994-11-24
EP0698109A1 (en) 1996-02-28
EP1211319A2 (en) 2002-06-05
DK0698109T3 (da) 2002-11-25
US20050048043A1 (en) 2005-03-03
DE69431106D1 (de) 2002-09-05
EP0698109B1 (en) 2002-07-31
ATE221575T1 (de) 2002-08-15
CA2162602A1 (en) 1994-11-24
AU6829994A (en) 1994-12-12
PT698109E (pt) 2002-12-31
JPH08509869A (ja) 1996-10-22

Similar Documents

Publication Publication Date Title
ES2180579T3 (es) Transferencia de genes en celulas epiteliales pancreaticas.
Samper-Martín et al. Polyphosphate degradation by Nudt3-Zn2+ mediates oxidative stress response
Dean DNA methylation and demethylation: a pathway to gametogenesis and development
WO2020198509A3 (en) Modified oligonucleotides with increased stability
PT1045897E (pt) Agentes terapeuticos por catalise enzimatica
ECSP088262A (es) Proteínas de fusión de albúmina
DK0973928T3 (da) DNA-baseret transposonsystem til indføring af nukleinsyre i DNA i en celle
BRPI0516515A (pt) composições contendo lipase, protease e amilase para o tratamento da insuficiência pancreática
IN2014DN07846A (es)
AR064509A1 (es) Promotores inducibles por el gen peroxidasa del nematodo y metodos de uso
BR112023021129A2 (pt) Composições e métodos para direcionamento de gene mediado por nuclease in vivo para o tratamento de distúrbios genéticos
Niu et al. S‐nitrosoglutathione reductase maintains mitochondrial homeostasis by promoting clearance of damaged mitochondria in porcine preimplantation embryos
JP2021520781A (ja) 体細胞リプログラミングおよびインプリンティングのモジュレートのための組成物および方法
ES2162148T3 (es) Acilacion enzimatica de un derivado de retinol.
ES2187047T3 (es) Composicion y metodo para la regulacion de la proliferacion celular y la muerte celular.
WO2006045105A3 (en) Generation and differentiation of adult stem cell lines
AR043862A1 (es) Procedimiento para la obtencion de estirpes celulares de mastocitos a partir de tejidos de cerdo y procedimiento para la produccion de moleculas de tipo de la heparina
ES2099714T3 (es) Procedimiento de tratamiento endoproteolitico de las proteinas (precursores) y de produccion microbiologica de proteinas.
Bernstein et al. Demethylation in early embryonic development and memory
ES2100173T3 (es) Procedimiento para la integracion de adn dirigida al sitio en el genoma de plantas.
Déglon Gene editing as a therapeutic strategy for spinocerebellar ataxia type-3
DE60136558D1 (de) Verfahren zur kultivierung humaner chondrozyten
DOP2007000020A (es) Modulación de la actividad de mdl-1 para el tratamiento de enfermedades inflamatorias
ES2194794T3 (es) Dendrimeros fosforados como agentes de transfeccion.
Araneda et al. Expression of Kin17 and 8-OxoG DNA glycosylase in cells of rodent and quail central nervous system